{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:32:11Z","timestamp":1790202731387,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T00:00:00Z","timestamp":1525910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the National Basic Research Program of China","award":["No. 2015CB932100"],"award-info":[{"award-number":["No. 2015CB932100"]}]},{"name":"the innovation team project of education department of Liaoning province","award":["LT 2014022"],"award-info":[{"award-number":["LT 2014022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13346-018-0534-4","type":"journal-article","created":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T18:01:22Z","timestamp":1525975282000},"page":"1162-1170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cytosine arabinoside prodrug designed to bind plasma serum albumin for drug delivery"],"prefix":"10.1007","volume":"8","author":[{"given":"Wei","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonggui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,10]]},"reference":[{"key":"534_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1021\/mp800200a","volume":"6","author":"YB Sun","year":"2008","unstructured":"Sun YB, Shi SL, Jing YK, Yin SL, Chen GL, Xu YJ, et al. Synthesis, transport and pharmacokinetics of 5\u2032-amino acid ester prodrugs of 1-D-arabinofuranosylcytosine. Mol Pharm. 2008;6:315\u201325.","journal-title":"Mol Pharm"},{"key":"534_CR2","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2147\/IJN.S76123","volume":"10","author":"YG Liu","year":"2015","unstructured":"Liu YG, Dai QL, Wang SB, Deng QJ, Wu WG, Chen AZ. Preparation and in vitro antitumor effects of cytosine arabinoside-loaded genipin-poly-l-glutamic acid-modified bacterial magnetosomes. Int J Nanomedicine. 2015;10:1387\u201397.","journal-title":"Int J Nanomedicine"},{"key":"534_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.leukres.2017.09.005","volume":"61","author":"JA Webster","year":"2017","unstructured":"Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, et al. Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia. Leuk Res. 2017;61:108\u201316.","journal-title":"Leuk Res"},{"issue":"3","key":"534_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/BF00686248","volume":"29","author":"LM DeAngelis","year":"1992","unstructured":"DeAngelis LM, Kreis W, Chan K, Dantis E, Akerman S. Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside. Cancer Chemother Pharmacol. 1992;29(3):173\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"534_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2165\/00003088-200241100-00002","volume":"41","author":"A Hamada","year":"2002","unstructured":"Hamada A, Kawaguchi T, Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin Pharmacokinet. 2002;41(10):705\u201318.","journal-title":"Clin Pharmacokinet"},{"key":"534_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cis.2017.06.012","volume":"246","author":"B Bhushan","year":"2017","unstructured":"Bhushan B, Khanadeev V, Khlebtsov B, Khlebtsov N, Gopinath P. Impact of albumin based approaches in nanomedicine: imaging, targeting and drug delivery. Adv Colloid Interf Sci. 2017;246:13\u201339.","journal-title":"Adv Colloid Interf Sci"},{"issue":"3","key":"534_CR7","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jconrel.2008.05.010","volume":"132","author":"F Kratz","year":"2008","unstructured":"Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008;132(3):171\u201383.","journal-title":"J Control Release"},{"issue":"12","key":"534_CR8","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.1016\/j.bbagen.2013.04.023","volume":"1830","author":"D Sleep","year":"2013","unstructured":"Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta. 2013;1830(12):5526\u201334.","journal-title":"Biochim Biophys Acta"},{"key":"534_CR9","first-page":"99","volume":"4","author":"E Miele","year":"2009","unstructured":"Miele E, Spinelli GP, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine. 2009;4:99\u2013105.","journal-title":"Int J Nanomedicine"},{"key":"534_CR10","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","volume":"17","author":"MR Green","year":"2006","unstructured":"Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17:1263\u20138.","journal-title":"Ann Oncol"},{"key":"534_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2183\/pjab.88.53","volume":"88","author":"H Maeda","year":"2012","unstructured":"Maeda H. Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88:53\u201371.","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"534_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","volume":"91","author":"H Maeda","year":"2015","unstructured":"Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev. 2015;91:3\u20136.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"534_CR13","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1039\/C6SC03862J","volume":"8","author":"J Mayr","year":"2017","unstructured":"Mayr J, Heffeter P, Groza D, Galvez L, Koellensperger G, Roller A, et al. An albumin-based tumor-targeted oxaliplatin prodrug with distinctly improved anticancer activity in vivo. Chem Sci. 2017;8(3):2241\u201350.","journal-title":"Chem Sci"},{"key":"534_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1593\/tlo.09109","volume":"2","author":"N Desai","year":"2009","unstructured":"Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol. 2009;2:59\u201364.","journal-title":"Transl Oncol"},{"issue":"11","key":"534_CR15","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1021\/acsnano.6b04268","volume":"10","author":"T Lin","year":"2016","unstructured":"Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, et al. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano. 2016;10(11):9999\u201310012.","journal-title":"ACS Nano"},{"key":"534_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2016.03.043","volume":"94","author":"SW Chung","year":"2016","unstructured":"Chung SW, Choi JU, Lee BS, Byun J, Jeon OC, Kim SW, et al. Albumin-binding caspase-cleavable prodrug that is selectively activated in radiation exposed local tumor. Biomaterials. 2016;94:1\u20138.","journal-title":"Biomaterials"},{"issue":"3","key":"534_CR17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1039\/C6BM00884D","volume":"5","author":"D Zhao","year":"2017","unstructured":"Zhao D, Zhang H, Tao W, Wei W, Sun J, He Z. A rapid albumin-binding 5-fluorouracil prodrug with a prolonged circulation time and enhanced antitumor activity. Biomater Sci. 2017;5(3):502\u201310.","journal-title":"Biomater Sci"},{"issue":"2","key":"534_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00280-009-0942-8","volume":"64","author":"K Abu Ajaj","year":"2009","unstructured":"Abu Ajaj K, Graeser R, Fichtner I, Kratz F. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol. 2009;64(2):413\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"534_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10549-011-1937-9","volume":"134","author":"K Abu Ajaj","year":"2012","unstructured":"Abu Ajaj K, Graeser R, Kratz F. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin. Breast Cancer Res Treat. 2012;134(1):117\u201329.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"534_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/pcan.2010.43","volume":"14","author":"B Elsadek","year":"2011","unstructured":"Elsadek B, Graeser R, Esser N, Schafer-Obodozie C, Tsurumi C, Abu Ajaj K, et al. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP). Prostate Cancer Prostatic Dis. 2011;14(1):14\u201321.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"534_CR21","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1517\/13543784.16.6.855","volume":"16","author":"F Kratz","year":"2007","unstructured":"Kratz F. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin Investig Drugs. 2007;16(6):855\u201366.","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"534_CR22","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1021\/acs.jmedchem.7b00049","volume":"60","author":"G Wang","year":"2017","unstructured":"Wang G, Chen H, Zhao D, Ding D, Sun M, Kou L, et al. Combination of l-carnitine with lipophilic linkage-donating gemcitabine derivatives as intestinal novel organic cation transporter 2-targeting oral prodrugs. J Med Chem. 2017;60(6):2552\u201361.","journal-title":"J Med Chem"},{"key":"534_CR23","doi-asserted-by":"crossref","unstructured":"Chen H, Wang G, Sun L, Zhang H, Sun M, Sun J et al. Regulating the alky chain length of fatty acid-didanosine prodrugs and evaluating its role in albumin binding. Drug Deliv Transl Res 2017","DOI":"10.1007\/s13346-017-0428-x"},{"issue":"8","key":"534_CR24","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1002\/jbm.a.34916","volume":"102","author":"S Absar","year":"2014","unstructured":"Absar S, Nahar K, Choi S, Ahsan F, Yang VC, Kwon YM. Serum albumin-protamine conjugate for biocompatible platform for targeted delivery of therapeutic macromolecules. J Biomed Mater Res A. 2014;102(8):2481\u201390.","journal-title":"J Biomed Mater Res A"},{"issue":"5","key":"534_CR25","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1021\/acs.bioconjchem.5b00143","volume":"26","author":"JG Mehtala","year":"2015","unstructured":"Mehtala JG, Kulczar C, Lavan M, Knipp G, Wei A. Cys34-PEGylated human serum albumin for drug binding and delivery. Bioconjug Chem. 2015;26(5):941\u20139.","journal-title":"Bioconjug Chem"},{"issue":"11","key":"534_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/jbt.21818","volume":"30","author":"X Hu","year":"2016","unstructured":"Hu X, Song W, Li W, Guo C, Yu Z, Liu R. Effects of gamma-irradiation on the molecular structures and functions of human serum albumin. J Biochem Mol Toxicol. 2016;30(11):525\u201332.","journal-title":"J Biochem Mol Toxicol"},{"issue":"9","key":"534_CR27","doi-asserted-by":"publisher","first-page":"16491","DOI":"10.3390\/molecules200916491","volume":"20","author":"ZY Tian","year":"2015","unstructured":"Tian ZY, Song LN, Zhao Y, Zang FL, Zhao ZH, Chen NH, et al. Spectroscopic study on the interaction between naphthalimide-polyamine conjugates and bovine serum albumin (BSA). Molecules. 2015;20(9):16491\u2013523.","journal-title":"Molecules"},{"issue":"2","key":"534_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s13346-016-0356-1","volume":"7","author":"W Tao","year":"2017","unstructured":"Tao W, Zhao D, Sun M, Li M, Zhang X, He Z, et al. Enzymatic activation of double-targeted 5'-O-L-valyl-decitabine prodrug by biphenyl hydrolase-like protein and its molecular design basis. Drug Deliv Transl Res. 2017;7(2):304\u201311.","journal-title":"Drug Deliv Transl Res."}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-018-0534-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-018-0534-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-018-0534-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T12:00:09Z","timestamp":1557489609000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-018-0534-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["534"],"URL":"https:\/\/doi.org\/10.1007\/s13346-018-0534-4","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,10]]},"assertion":[{"value":"10 May 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}